ResMed Inc (RMD) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software.
Total Cash From Operating Activities Chart for ResMed Inc
ResMed Inc (RMD) operating cash flow for FY2026 was USD 1.8B, a 3.1% change from FY2025. ResMed Inc's operating cash flow grew from USD 1.0M in 1993 to USD 1.8B in 2026 (180482.9% over 33 years). Operating cash flow compound annual growth rate: 5-year CAGR of 19.6%, 10-year CAGR of 12.7%, 20-year CAGR of 15.6%.
Total Cash From Operating Activities (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $32.38B
- Implied Share Price
- $224.46
- Enterprise Value
- $31.74B
- Revenue (TTM)
- $5.65B
- EBITDA
- $2.10B
- Profit Margin
- 26.95%
- Trailing P/E
- 21.50
- Forward P/E
- 18.69
- Price/Book (MRQ)
- 4.92
- Price/Sales (TTM)
- 5.73
- EV/EBITDA
- 14.74
- EV/Revenue
- 5.61
- Dividend Yield
- 1.06%
- Book Value
- $45.51
- Free Cash Flow (FY2026)
- $1.65B
- Free Cash Flow Yield
- 5.09%
Snapshot as of 16th August 2026 — not point-in-time controlled, may lag the live market by a few days.